Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity

v3.22.2.2
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance at Dec. 31, 2020 $ (1,979) $ 6 $ 144,156 $ (145,803) $ (338)
Beginning balance (in shares) at Dec. 31, 2020   56,371,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Release of restricted stock (in shares)   1,784,000      
Exercise of stock options, net of vesting of restricted shares 71   71    
Exercise of stock options, net of vesting of restricted shares (in shares)   133,000      
Issuance of common stock for payment of board of director fees 66   66    
Issuance of common stock for payment of board of director fees (in shares)   99,000      
Sales of common stock, net of issuance costs 32,708 $ 2 32,706    
Sales of common stock, net of issuance costs (in shares)   17,162,000      
Stock-based compensation expense 3,888   3,888    
Cumulative translation adjustment (18)       (18)
Net income (loss) (21,711)     (21,711)  
Ending balance at Sep. 30, 2021 13,025 $ 8 180,887 (167,514) (356)
Ending balance (in shares) at Sep. 30, 2021   75,549,000      
Beginning balance at Jun. 30, 2021 9,052 $ 7 177,254 (167,886) (323)
Beginning balance (in shares) at Jun. 30, 2021   72,736,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Release of restricted stock (in shares)   772,000      
Exercise of stock options, net of vesting of restricted shares 1   1    
Exercise of stock options, net of vesting of restricted shares (in shares)   2,000      
Sales of common stock, net of issuance costs 2,171 $ 1 2,170    
Sales of common stock, net of issuance costs (in shares)   2,039,000      
Stock-based compensation expense 1,462   1,462    
Cumulative translation adjustment (33)       (33)
Net income (loss) 372     372  
Ending balance at Sep. 30, 2021 13,025 $ 8 180,887 (167,514) (356)
Ending balance (in shares) at Sep. 30, 2021   75,549,000      
Beginning balance at Dec. 31, 2021 $ 65,277 $ 10 264,944 (199,325) (352)
Beginning balance (in shares) at Dec. 31, 2021 96,751,610 96,752,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Release of restricted stock (in shares)   1,409,000      
Exercise of stock options, net of vesting of restricted shares $ 16   16    
Exercise of stock options, net of vesting of restricted shares (in shares)   23,000      
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. 1,814   1,814    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   848,000      
Issuance of common stock under the 2018 employee stock purchase plan 116   116    
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   96,000      
Sales of common stock, net of issuance costs 3,654   3,654    
Sales of common stock, net of issuance costs (in shares)   2,193,000      
Stock-based compensation expense 2,113   2,113    
Cumulative translation adjustment (201)       (201)
Net income (loss) (40,006)     (40,006)  
Ending balance at Sep. 30, 2022 $ 32,783 $ 10 272,657 (239,331) (553)
Ending balance (in shares) at Sep. 30, 2022 101,321,268 101,321,000      
Beginning balance at Jun. 30, 2022 $ 35,693 $ 10 267,465 (231,313) (469)
Beginning balance (in shares) at Jun. 30, 2022   98,137,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Release of restricted stock (in shares)   527,000      
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. 689   689    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   464,000      
Sales of common stock, net of issuance costs 3,654   3,654    
Sales of common stock, net of issuance costs (in shares)   2,193,000      
Stock-based compensation expense 849   849    
Cumulative translation adjustment (84)       (84)
Net income (loss) (8,018)     (8,018)  
Ending balance at Sep. 30, 2022 $ 32,783 $ 10 $ 272,657 $ (239,331) $ (553)
Ending balance (in shares) at Sep. 30, 2022 101,321,268 101,321,000